AI Article Synopsis
- Myeloproliferative neoplasms (MPNs) often have a common mutation (JAK2 V617F) in about 70% of cases, leading to a focus on developing targeted therapies with JAK2 inhibitors.
- Recent research has identified several drugs targeting crucial pathways for MPN development, including JAK-STAT and PI3K/AKT/mTOR, which have shown effectiveness in reducing spleen size and alleviating symptoms.
- JAK2 inhibitors are particularly beneficial for patients with splenomegaly or constitutional symptoms, but those with low hemoglobin levels need to be cautious as the treatment may temporarily increase the need for blood transfusions.
Article Abstract
Purpose Of Review: Myeloproliferative neoplasms (MPNs) are diseases that carry the JAK2 (V617F) mutation in about 70% of the patients. The purpose of this review is to describe the recent advances in the therapy of MPNs with JAK2 inhibitors.
Recent Findings: Many drugs are now under investigations targeting different pathways critical for MPN development, such as the JAK-STAT (JAK2 inhibitors: INCB018424 or ruxolitinib, TG101348 or SAR302503, CYT387, SB1518, CEP701 and LY2784544) and the PI3K/AKT/mTOR (everolimus) pathways, or act through remodeling of chromatin with a key role in epigenetics (givinostat, panobinostat and vorinostat). The most relevant effects were spleen size reduction and relief of constitutional symptoms.
Summary: Patients who might benefit from JAK2 inhibitors in clinical practice are mostly those with splenomegaly or with constitutional symptoms. We should alert patients with lower hemoglobin levels that these therapies might, although temporarily, favor the need for red blood cell transfusions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOH.0b013e32834ff575 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!